Zheng Ren

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

G. Cutter, C. Hotermans, J. Goldberg, 2019, Neurology.

Natalizumab Extended Interval Dosing Is Associated with a Reduction in Progressive Multifocal Leukoencephalopathy (PML) Risk in the Touch® Registry

G. Cutter, C. Hotermans, J. Goldberg, 2018 .

Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the TOUCH® Prescribing Program

G. Cutter, C. Hotermans, J. Goldberg, 2019, Revue Neurologique.

071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program

G. Cutter, C. Hotermans, J. Goldberg, 2018, Journal of Neurology, Neurosurgery, and Psychiatry.